Search Follow us


1 - 12 of 34
Sort by: popularity | newest
Page  2 3  of 3 | Next

PTSD programme on track for results in Q3

Update | Pharmaceuticals & healthcare | 24 Aug 2018

The fiscal year 2018, which ended in June, was a major transition for Bionomics as it realigned itself to focus on disorders of the central nervous system. This strategy hinges on the company’s lead asset BNC210, a negative allosteric modulator of the α7 nicotinic acetylcholine receptor, which has a potentially novel anxiolytic mechanism of action. The drug is in Phase IIb for post-traumatic stress disorder (PTSD) (with a readout expected in this quarter) and Phase IIa for agitation in the elderly.


RESTORE trial completed, data this quarter

Update | Pharmaceuticals & healthcare | 18 Jul 2018

Bionomics announced on 9 July 2018 that it had completed treatment in its 193-patient Phase II clinical study of BNC210 for post-traumatic stress disorder (PTSD). The RESTORE clinical study completed the treatment phase on time and the company stated that it intends to provide topline data by the end of calendar Q318.


Phase IIa in agitation of the elderly initiated

Update | Pharmaceuticals & healthcare | 29 May 2018

Bionomics announced on 23 May 2018 it has initiated a Phase IIa study of its α7 nicotinic receptor inhibitor for the treatment of agitation in the elderly in a hospital setting. Agitation is a common problem (13-24%) in patients with dementia, and we expect the trial to focus primarily on this population. It will enrol a target of 40 patients across Australia and is expected to provide top-line data in calendar Q119.


Novel mechanisms in drug discovery

Initiation | Pharmaceuticals & healthcare | 10 Apr 2018

We are re-initiating coverage on Bionomics, a pharmaceutical company developing drugs for neuropsychiatric indications and oncology. It has leveraged its ionX and MultiCore development platforms to identify BNC210, a drug with a novel anxiolytic mechanism currently in Phase IIb for post-traumatic stress disorder (PTSD). It has also leveraged this platform with partner Merck to target cognitive dysfunction associated with Alzheimer’s disease, in a deal worth US$506m in milestones plus royalties. We re-initiate with a valuation of A$418.7m or A$0.87 per share.


A novel method of treating anxiety disorders

QuickView | Pharmaceuticals & healthcare | 18 Dec 2017

Bionomics’ lead programme is BNC210 for the treatment of anxiety-related disorders. The drug is an orally bioavailable small molecule targeting the α7 nicotinic acetylcholine receptor, which has been implicated in the brain’s response to anxiety. It is currently being tested in a randomized, double-blind Phase IIb clinical study of 192 post-traumatic stress disorder (PTSD) patients, with top-line results expected in H218.

Anteo Diagnostics

ASX Spotlight conference book May 2015

Sector Commentary: | *Multiple Sectors | 22 May 2015



Increasingly integrated business

Outlook | Pharmaceuticals & healthcare | 09 Feb 2015

Bionomics has announced a number of strategic initiatives in recent months. In mid-2014, it entered into a second partnered programme with Merck & Co. In October, it acquired Prestwick Chemical, reinforcing its early-stage drug delivery and discovery functions. More recently, Bionomics secured a loan of US$10m to finance the development of BNC210, which it reacquired from Ironwood Pharma, starting a Phase Ib trial in February.

Benitec Biopharma

ASX Spotlight Conference book

Sector Commentary: | Pharmaceuticals & healthcare | 13 Oct 2014



Edison healthcare quarterly: It’s getting personal

Sector Commentary: | Pharmaceuticals & healthcare | 30 Jun 2014



Poised for key RCC data

Update | Pharmaceuticals & healthcare | 10 Mar 2014

Bionomics will shortly see the outcome of its Phase II study of its lead drug, the vascular disrupting agent (VDA) BNC105, in second-line renal cell carcinoma. In our view, this represents a major stock price catalyst. Bionomics has recently reported an encouraging response rate in the first stage of its separate Phase I/II trial of BNC105 in recurrent ovarian cancer. We have updated our current risk-adjusted NPV to A$338m, equivalent to A$0.80/share ahead of the outcome of BNC105 in RCC. We note that a positive outcome in the RCC study, and a move into Phase III, would potentially boost the valuation to c A$413m or A$0.99/share.


Edison healthcare quarterly: A boost for allergy immunotherapy

Sector Commentary: | Pharmaceuticals & healthcare | 05 Mar 2014


Anteo Diagnostics

ASX Spotlight Conference – London, 6 March 2014

Sector Commentary: | Pharmaceuticals & healthcare | 04 Mar 2014